First Time Loading...

ContraFect Corp
NASDAQ:CFRX

Watchlist Manager
ContraFect Corp Logo
ContraFect Corp
NASDAQ:CFRX
Watchlist
Price: 0.0271 USD -16.62% Market Closed
Updated: Mar 29, 2024

Intrinsic Value

CFRX doesn't have a meaningful market cap.
CFRX's intrinsic value estimate is unreliable because it is based only on its DCF value and doesn't use a relative valuation using multiples.

ContraFect Corp. is a clinical stage biotechnology company, which engages in discovering and developing direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for... [ Read More ]

The intrinsic value of one CFRX stock under the Base Case scenario is 2.6909 USD. Compared to the current market price of 0.0271 USD, ContraFect Corp is Undervalued by 99%.

Key Points:
CFRX Intrinsic Value
Base Case
2.6909 USD
Undervaluation 99%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Fundamental Analysis

How can I assist you today?

Provide an overview
of ContraFect Corp's business.

What risks and challenges
does ContraFect Corp face in the near future?

Summarize the latest earnings report
of ContraFect Corp.

Provide P/E
for ContraFect Corp and its competitors.

Financials

Balance Sheet Decomposition
ContraFect Corp

Current Assets 16.5m
Cash & Short-Term Investments 14.4m
Receivables 600k
Other Current Assets 1.5m
Non-Current Assets 2.7m
PP&E 2.6m
Other Non-Current Assets 110k
Current Liabilities 16.5m
Accounts Payable 11.6m
Accrued Liabilities 4.9m
Other Current Liabilities -10k
Non-Current Liabilities 3.9m
Other Non-Current Liabilities 3.9m
Efficiency

Earnings Waterfall
ContraFect Corp

Revenue
0 USD
Operating Expenses
-39.3m USD
Operating Income
-39.3m USD
Other Expenses
3.5m USD
Net Income
-35.9m USD

Free Cash Flow Analysis
ContraFect Corp

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

CFRX Profitability Score
Profitability Due Diligence

ContraFect Corp's profitability score is 33/100. The higher the profitability score, the more profitable the company is.

33/100
Profitability
Score

ContraFect Corp's profitability score is 33/100. The higher the profitability score, the more profitable the company is.

CFRX Solvency Score
Solvency Due Diligence

ContraFect Corp's solvency score is 35/100. The higher the solvency score, the more solvent the company is.

Low D/E
Short-Term Solvency
Long-Term Solvency
Low Altman Z-Score
35/100
Solvency
Score

ContraFect Corp's solvency score is 35/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

CFRX Price Targets Summary
ContraFect Corp

There are no price targets for CFRX.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

CFRX Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

CFRX Price
ContraFect Corp

1M 1M
-
6M 6M
-95%
1Y 1Y
-99%
3Y 3Y
-100%
5Y 5Y
-100%
10Y 10Y
-100%
Annual Price Range
0.0271
52w Low
0.0262
52w High
2.29
Price Metrics
Average Annual Return -26.48%
Standard Deviation of Annual Returns 60.06%
Max Drawdown -100%
Shares Statistics
Market Capitalization 145.2k USD
Shares Outstanding 5 358 800
Percentage of Shares Shorted 2.75%

CFRX Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

ContraFect Corp Logo
ContraFect Corp

Country

United States of America

Industry

Biotechnology

Market Cap

145.2k USD

Dividend Yield

0%

Description

ContraFect Corp. is a clinical stage biotechnology company, which engages in discovering and developing direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. The company is headquartered in Yonkers, New York and currently employs 38 full-time employees. The company went IPO on 2014-07-29. The firm is focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its lead DLA product candidate, exebacase (CF-301), is used for the treatment of methicillin-resistant S. aureus (MRSA) bloodstream infections (bacteremia), including right-sided endocarditis, when used in addition to standard-of-care (SOC) anti-staphylococcal antibiotics in adult patients. Its other product candidate, CF-370, is designed to target a range of gram-negative bacteria, including P. aeruginosa and has demonstrated potent in vivo activity against extensively drug-resistant (XDR) strains. The company has developed an, engineered variant of exebacase, known as CF-296. The company is conducting further in vitro and in vivo characterization of CF-296 to evaluate the full profile of this compound.

Contact

NEW YORK
Yonkers
28 Wells Ave Ste 3
+19142072300.0
https://www.contrafect.com/

IPO

2014-07-29

Employees

38

Officers

Chairman, CEO & Pres
Dr. Roger James Pomerantz F.A.C.P., FACP, M.D.
Chief Financial Officer
Mr. Michael Messinger CPA, CPA
Gen. Counsel, Corp. Sec. & Data Protection Officer
Ms. Natalie Bogdanos J.D.
VP of HR
Mr. Matthew Salamone P.H.R., SPHR
Sr. VP of Translational Sciences & Preclinical Devel.
Dr. Gary Woodnutt

See Also

Discover More